Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in advanced pancreatic cancer (JANUS 2)
NCT02119663Phase 3Terminated
- Sponsor
- Incyte
- Start
- Jun 2014
- Primary completion
- Feb 2016
- Countries
- 14
01
Overview
A Phase 3 trial of ruxolitinib in pancreatic adenocarcinoma (PDAC), sponsored by Incyte. Started Jun 2014; status: terminated.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02119663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02119663.